Colorectal cancer, First line treatment, Immunotherapy, Efficacy, Safety
chronic obstructive pulmonary disease, colorectal cancer, fatty acid, multi-omics, mediating factor
gastric cancer, first line treatment, immunotherapy, HER2-negative, safety